Showing results (271-280 of 323) with videos related to

Sort By:
Pageof 33
JAMA Network Open|August 8, 2024
Early Integrated Palliative Care in Patients With Advanced Cancer: A Randomized Clinical TrialEunKyo Kang, Jung Hun Kang, Su-Jin Koh, et al.
Annals of Hematology|October 14, 2025
Prognostic impact of GNRI-IPI score in octogenarians with diffuse large B-Cell lymphoma treated with R-CHOPEun-Jeong Jeong, Woochan Park, Jeongmin Seo, et al.
Cancer Research and Treatment|March 14, 2025
Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic HospitalJin Won Kim, Jung-Yeon Choi, Woochan Park, et al.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysisHidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARDIsamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Journal of Pain and Symptom Management|September 4, 2025
Quality Matters: Effect of High-Quality Early Palliative Care in Advanced CancerEunKyo Kang, Su-Jin Koh, Jung Hun Kang, et al.
The American Journal of Hospice & Palliative Care|February 14, 2020
The Impacts of Prognostic Awareness on Mood and Quality of Life Among Patients With Advanced CancerEunKyo Kang, Jung Hun Kang, Su-Jin Koh, et al.
Cardiovascular Diabetology|July 10, 2025
Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort studyJi Yun Lee, Ju-Hyun Lee, Eun-Jung Jung, et al.
Cancer Medicine|March 27, 2018
Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide surveyShin Hye Yoo, Miso Kim, Young Ho Yun, et al.
Oncotarget|October 4, 2017
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines releaseKoung Jin Suh, Ji Hea Sung, Jin Won Kim, et al.
Pageof 33